- Home
- TFFP vs ALZN Comparison
TFFP vs ALZN Comparison
Compare TFFP & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFFP
- ALZN
- Stock Information
- Founded
- TFFP 2018
- ALZN 2016
- Country
- TFFP United States
- ALZN United States
- Employees
- TFFP N/A
- ALZN N/A
- Industry
- TFFP Biotechnology: Pharmaceutical Preparations
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- TFFP Health Care
- ALZN Health Care
- Exchange
- TFFP Nasdaq
- ALZN Nasdaq
- Market Cap
- TFFP 6.9M
- ALZN 7.0M
- IPO Year
- TFFP 2019
- ALZN 2021
- Fundamental
- Price
- TFFP $0.07
- ALZN $1.27
- Analyst Decision
- TFFP Strong Buy
- ALZN Strong Buy
- Analyst Count
- TFFP 1
- ALZN 1
- Target Price
- TFFP $44.00
- ALZN $32.00
- AVG Volume (30 Days)
- TFFP 5.0M
- ALZN 146.8K
- Earning Date
- TFFP 11-20-2024
- ALZN 12-24-2024
- Dividend Yield
- TFFP N/A
- ALZN N/A
- EPS Growth
- TFFP N/A
- ALZN N/A
- EPS
- TFFP N/A
- ALZN N/A
- Revenue
- TFFP $1,161,210.00
- ALZN N/A
- Revenue This Year
- TFFP $60.25
- ALZN N/A
- Revenue Next Year
- TFFP N/A
- ALZN N/A
- P/E Ratio
- TFFP N/A
- ALZN N/A
- Revenue Growth
- TFFP 24.55
- ALZN N/A
- 52 Week Low
- TFFP $0.06
- ALZN $1.06
- 52 Week High
- TFFP $11.00
- ALZN $15.06
- Technical
- Relative Strength Index (RSI)
- TFFP 20.20
- ALZN 49.66
- Support Level
- TFFP $0.06
- ALZN $1.16
- Resistance Level
- TFFP $0.31
- ALZN $1.34
- Average True Range (ATR)
- TFFP 0.04
- ALZN 0.08
- MACD
- TFFP 0.03
- ALZN 0.02
- Stochastic Oscillator
- TFFP 1.12
- ALZN 89.29
About TFFP TFF Pharmaceuticals Inc.
TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.